Humanized antibodies to LIV-1 and use of same to treat cancer
US9783608B2 · kind B2 · utility
3Cited by
13References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 20, 2015 |
| Grant date | Oct 10, 2017 |
| Priority date | — |
| Expiry date | Nov 22, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.